High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent

被引:41
作者
Fouchier, SW
Sankatsing, RR
Peter, J
Castillo, S
Pocovi, M
Alonso, R
Kastelein, JJP
Defesche, JC
机构
[1] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1100 DD Amsterdam, Netherlands
[2] Univ Zaragoza, Dept Biochem, Zaragoza, Spain
[3] Fdn Jimenez Diaz, Lipid Unit Res, E-28040 Madrid, Spain
关键词
D O I
10.1136/jmg.2004.029454
中图分类号
Q3 [遗传学];
学科分类号
071007 [遗传学]; 090102 [作物遗传育种];
摘要
Background: Familial hypobetalipoproteinaemia (FHBL) is an autosomal co-dominant hereditary disorder of lipoprotein metabolism characterised by decreased low density lipoprotein (LDL) cholesterol and apolipoprotein B (APOB) plasma levels. High levels of plasma APOB and LDL cholesterol are strong predictors for risk of cardiovascular disease (CVD), while individuals with low APOB and LDL cholesterol levels are thought to have lower than average risk for CVD, and in fact, heterozygous FHBL patients appear to be asymptomatic. Methods: Rather than identifying truncated APOB proteins in plasma fractions separated by gel electrophoresis, which will miss any mutations in proteins smaller than 30 kb, we analysed the APOB gene directly, using PCR. Results: We identified nine different mutations, six of which are novel. Each mutation showed complete co-segregation with the FHBL phenotype in the families, and statistically significant differences between carriers and non-carriers were found for plasma total, LDL, and HDL cholesterol, triglycerides, and APOB levels, but not for APOA1 levels. All carriers of an APOB mutation were completely free from CVD. Conclusions: Prolonged low levels of LDL cholesterol and elevated levels of HDL cholesterol may reduce the progression of atherosclerotic disease, but this has not been unequivocally shown that this is indeed the case in individuals with FHBL, and is the subject of a current study.
引用
收藏
页数:4
相关论文
共 23 条
[1]
A novel nontruncating APOB gene mutation, R463W, causes familial hypobetalipoproteinemia [J].
Burnett, JR ;
Shan, J ;
Miskie, BA ;
Whitfield, AJ ;
Yuan, J ;
Tran, K ;
McKnight, CJ ;
Hegele, RA ;
Yao, ZM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (15) :13442-13452
[2]
FARESE RV, 1992, J LIPID RES, V33, P569
[3]
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[4]
GOTTO AM, 1984, CIRCULATION, V69, P1067
[5]
GROENEWEGEN WA, 1994, J LIPID RES, V35, P1012
[6]
Cholesterol and coronary heart disease - The 21st century [J].
Grundy, SM .
ARCHIVES OF INTERNAL MEDICINE, 1997, 157 (11) :1177-1184
[7]
KANE GP, 1995, METABOLIC MOL BASIS, P1853
[8]
A cholesterol-lowering gene maps to chromosome 13q [J].
Knoblauch, H ;
Müller-Myhsok, B ;
Busjahn, A ;
Ben Avi, L ;
Bähring, S ;
Baron, H ;
Heath, SC ;
Uhlmann, R ;
Faulhaber, HD ;
Shpitzen, S ;
Aydin, A ;
Reshef, A ;
Rosenthal, M ;
Eliav, O ;
Mühl, A ;
Lowe, A ;
Schurr, D ;
Harats, D ;
Jeschke, E ;
Friedlander, Y ;
Schuster, H ;
Luft, FC ;
Leitersdorf, E .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 66 (01) :157-166
[9]
LINTON MF, 1993, J LIPID RES, V34, P521
[10]
READING-FRAME RESTORATION WITH AN APOLIPOPROTEIN-B GENE FRAMESHIFT MUTATION [J].
LINTON, MF ;
PIEROTTI, V ;
YOUNG, SG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) :11431-11435